ストックスクリーナーアプリを入手
1,122.50
0.61%
-6.85
アフターアワーズ：
1122.80
0.30
+0.03%
前日終値:
$1,129.35
開ける：
$1138.82
24時間の取引高:
2.26M
Relative Volume:
0.71
時価総額：
$1.00T
収益：
$72.25B
当期純損益:
$25.28B
株価収益率:
40.41
EPS:
27.781
ネットキャッシュフロー:
$10.37B
1週間 パフォーマンス:
-1.94%
1か月 パフォーマンス:
+11.70%
6か月 パフォーマンス:
+6.47%
1年 パフォーマンス:
+39.00%
1日の値動き範囲:
$1,115.50
$1,146.68
1週間の範囲:
$1,112.01
$1,170.12
52週間の値動き範囲:
$623.78
$1,182.73
Lilly Eli Co Stock (LLY) Company Profile
Compare LLY vs JNJ, ABBV, NVS, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,122.50 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
235.18 | 567.28B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
222.47 | 391.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
150.93 | 289.19B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
115.17 | 283.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-12-16 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 繰り返されました | BofA Securities | Buy |
| 2025-12-15 | 繰り返されました | Goldman | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-10 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 繰り返されました | BMO Capital Markets | Outperform |
| 2025-10-14 | アップグレード | Erste Group | Hold → Buy |
| 2025-09-17 | ダウングレード | Berenberg | Buy → Hold |
| 2025-08-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2025-08-18 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | ダウングレード | Erste Group | Buy → Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-09-13 | 再開されました | Citigroup | Buy |
| 2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
| 2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
| 2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-20 | 再開されました | UBS | Buy |
| 2023-08-09 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-26 | 繰り返されました | Citigroup | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-24 | 繰り返されました | BofA Securities | Buy |
| 2023-05-24 | 繰り返されました | UBS | Buy |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-09-22 | アップグレード | UBS | Neutral → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-03-10 | 開始されました | Daiwa Securities | Outperform |
| 2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-16 | 繰り返されました | BofA Securities | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-21 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
| 2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-03-12 | 開始されました | JP Morgan | Overweight |
| 2019-01-23 | 開始されました | UBS | Buy |
| 2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-10-01 | 繰り返されました | SunTrust | Buy |
| 2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool
Eli Lilly Broadens Oncology Story With Jaypirca CLL Win And JAK2 Advance - simplywall.st
Lilly bet $2.3B on a Cambridge biotech and its first clinical trial just showed why - MassLive
GLP-1s, Eli Lilly to upgrade Alabama economy - The Business Journals
Early trial data points to Eli Lilly's AJ1-11095 in myelofibrosis - AD HOC NEWS
Why Eli Lilly's Oral Medicine Is Turning Heads? - Kalkine Media
Lilly Backs Abridge to Bring Ambient AI Into Clinical Trial Recruitment - AIM Media House
Eli Lilly Eyes Label Expansion For Leukemia Drug - Benzinga
Lilly Sues Cipla to Block Copy of Breast Cancer Drug Verzenio - Bloomberg Law News
BMO reiterates Outperform on Eli Lilly stock, cites JAK2i data - Investing.com
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - Moomoo
Is LLY Overvalued? DCF Says Worth $762 - GuruFocus
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400 - Moomoo
Eli Lilly JAK2 Data Highlights Pipeline Beyond Obesity And Valuation Upside - Yahoo Finance
Eli Lilly (LLY) Reports Promising Phase 1 Study Results for New Myelofibrosis Treatment - GuruFocus
Eli Lilly (LLY) Reports Promising Phase 3 Trial Results for Jayp - GuruFocus
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow - AOL.com
Eli Lilly & Co Shs Cert Deposito Arg Repr 0.14285714 Shs Trade Ideas — BCBA:LLY.CI - TradingView
Eli Lilly & Co. Stock (US5324571083): Weekly technical picture in focus - AD HOC NEWS
Lilly's Jaypirca significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL - Investing News Network
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL - investor.lilly.com
Eli Lilly & Co. Stock (US5324571083): Novo Nordisk peer check keeps obesity drug leader in focus - AD HOC NEWS
Is Eli Lilly (LLY) One Of The Most Profitable Blue Chip Stocks To Buy According To Hedge Funds? - Insider Monkey
Lilly trial drug cuts spleen size, symptoms in myelofibrosis - Stock Titan
Jim Cramer Wasn’t Selling Eli Lilly (LLY) - Insider Monkey
Abridge Secures Strategic Investment From Eli Lilly, Expands AI Platform Into Payer and Research Workflows - Digital Health News
LLY News | ELI LILLY & CO (NYSE:LLY) - ChartMill
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance Australia
Eli Lilly & Co. stock underperforms Friday when compared to competitors - MarketWatch
Is Eli Lilly's Growth Story Still Gaining Strength? - Kalkine Media
Eli Lilly’s Abridge Bet Links Healthcare AI To Valuation And Growth - Yahoo Finance
The Catch Hiding In Eli Lilly Stock’s Growth Story - Trefis
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About - The Globe and Mail
Eli Lilly (LLY) Moves to Enforce 340B Claims Data Reporting Compliance - Insider Monkey
Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy - Yahoo Finance
Prometheus raises $12 billion in capital for artificial engineers - statnews.com
Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline - Insider Monkey
Eli Lilly and Company $LLY is Xponance LLC's 10th Largest Position - MarketBeat
American Express, Live Nation And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Eli Lilly donates $50,000 to Kenosha YMCA for teen services - Kenosha News
Polen Capital Management LLC Lowers Position in Eli Lilly and Company $LLY - MarketBeat
Kovack Advisors Inc. Purchases 3,506 Shares of Eli Lilly and Company $LLY - MarketBeat
IFM Investors Pty Ltd Boosts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Stock Position Boosted by Parnassus Investments LLC - MarketBeat
Nuveen LLC Raises Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
The Catch Hiding In Eli Lilly Stock's Growth Story - Trefis
Eli Lilly and Company (LLY)’s Foundayo Hits New Weight Loss Milestone among Menopause Ladies - Insider Monkey
Eli Lilly Stock Outlook 2026: The Retatrutide Upgrade Cycle - EBC Financial Group
Insider Sell: Ilya Yuffa Sells 2,500 Shares of Eli Lilly and Co (LLY) - GuruFocus
Eli Lilly and Company (NYSE:LLY) Shares Up 2.2%What's Next? - MarketBeat
Eli Lilly Insider Sold Shares Worth $2,876,925, According to a Recent SEC Filing - Moomoo
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
0.20%
0.40%
大文字化:
|
ボリューム (24 時間):